VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Foot-and-Mouth Disease Virus Cationic Microparticle-coated DNA Vaccine Foot-and-Mouth Disease Virus DNA Vaccine pSinCMV-Vac-MEG990
Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004552
  • Type: DNA vaccine
  • Status: Research
  • 1D gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Vector: pVAC-1D (Reddy et al., 2012)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004551
  • Type: DNA vaccine
  • Status: Research
  • Antigen: the FMDV-specific MEG990 gene - 3 VP1 genes (Dar et al., 2012)
  • 1D gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • 1D gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • 1D gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response

Guinea pig Response

  • Vaccination Protocol: Sixty male guinea pigs of 10 weeks of age were divided in to three groups each containing 20 animals. Group I was inoculated with a 10 µg of pVAC- 1D (naked DNA vaccinated group), group II was inoculated with pVAC-1D coated on PLG microparticles (pVAC-1D + PLG group) and group III received PBS. All the animals were inoculated intramuscularly in the gluteal region of the right leg (Reddy et al., 2012).
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Immunization with pVAC 1D-PLG elicited significantly enhanced neutralization antibody responses compared to naked DNA vaccine (Reddy et al., 2012).
  • Efficacy: Microparticles coated plasmid DNA-injected guinea pigs were protected when challenged with FMD virus (Reddy et al., 2012).

Guinea pig Response

  • Vaccination Protocol: Immunization of guinea pigs with the construct at dose rate of 10, 5, 2 and 1 μg per animal was through an intramuscular route (Dar et al., 2012).
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Immune responses included significant neutralizing antibody induction at all doses against all serotypes tested as compared to non-immunized controls, and delayed appearance and reduced severity of FMD lesions (Dar et al., 2012).
  • Challenge Protocol: Viral challenge of guinea pigs was 4 week post-immunization with 1000 GPID(50) of FMDV serotype A (Dar et al., 2012).
  • Efficacy: Two of six and one of six guinea pigs were completely protected in 10 and 5 μg immunized groups (Dar et al., 2012).
References References